HDAC9 and cervical adenocarcinoma: We confirmed that MPT0E028 inhibited nuclear HDAC activity in the cervical adenocarcinoma cell line HeLa (IC50 = 11.1±2.8 nM) and in HCT116 cells (IC50 = 4.43±0.5 μM), which were approximately 9–30 times more potent than SAHA (IC50 = 118.8±13.2 nM and 129.4±13.9 μM, respectively) (Figure 3A and 3B).